Pharmacophore modeling and 3D QSAR studies for prediction of matrix metalloproteinases inhibitory activity of hydroxamate derivatives

Combs, 2007, Structure-based drug design of new leads for phosphatase research, Investigational Drugs, 10, 112 Coumar, 2009, Structure-based drug design of novel Aurora kinase A inhibitors: Structural basis for potency and specificity, Journal of Medicinal Chemistry, 52, 1050, 10.1021/jm801270e Dixon, 2006, PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results, Journal of Computer Aided Molecular Design, 20, 647, 10.1007/s10822-006-9087-6 Dureja, 2007, Topochemical models for the prediction of lipophilicity of 1,3-disubstituted propan-2-one analogs, Journal of Theoretical and Computational Chemistry, 6, 435, 10.1142/S021963360700309X Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nature Reviews Cancer, 2, 161, 10.1038/nrc745 Folkman, 1971, Tumor angiogenesis: Therapeutic implications, New England Journal of Medicine, 285, 1182, 10.1056/NEJM197111182852108 Guner, 2000 Gupta, 2015, QSAR studies on hydroxamic acids: A fascinating family of chemicals with a wide spectrum of activities, Chemical Reviews, 115, 6427, 10.1021/cr500483r Johnson, 1998, Matrix metalloproteinases, Current Opinion in Chemical Biology, 2, 466, 10.1016/S1367-5931(98)80122-1 Katritzky, 1996, Correlation of boiling points with molecular structure. 1. A training set of 298 diverse organics and a test set of 9 simple inorganics, Journal of Physical Chemistry, 100, 10400, 10.1021/jp953224q Khan, 2010, Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database, Bioinformation, 5, 62, 10.6026/97320630005062 Kontogiorgis, 2005, Matrix metalloproteinase inhibitors: A review on pharmacophore mapping and (Q)SARs results, Current Medicinal Chemistry, 12, 339, 10.2174/0929867053363243 Lather, 2008, QSAR models for prediction of glycogen synthase kinase-3b inhibitory activity of indirubin derivatives, QSAR Combinatorial Science, 27, 718, 10.1002/qsar.200730052 Li, 2003, Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix, Microscopy Research & Technique, 60, 107, 10.1002/jemt.10249 Liekens, 2001, Angiogenesis: Regulators and clinical applications, Biochemical Pharmacology, 61, 253, 10.1016/S0006-2952(00)00529-3 Mori, 2013, Discovery of a new class of potent MMP inhibitors by structure based optimization of the arylsulfonamide scaffold, ACS Medicinal Chemistry Letters, 4, 565, 10.1021/ml300446a Morphy, 1995, Matrix metalloproteinase inhibitors: Current status, Current Medicinal Chemistry, 2, 743, 10.2174/092986730203220224091658 Mustata, 2011, Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death, Current Topics in Medicinal Chemistry, 11, 281, 10.2174/156802611794072641 Nirmala, 2016 Phase, 2008 Rathee, 2013, Iridoid glycosides-Kutkin, Picroside I, and Kutkoside from Picrorrhiza kurroa Benth inhibits the invasion and migration of MCF-7 breast cancer cells through the down regulation of matrix metalloproteinases, Arabian Journal of Chemistry, 6, 49, 10.1016/j.arabjc.2011.01.011 Roy, 2001, QSAR of matrix metalloproteinase inhibitor N-[(substituted phenyl)sulfonyl]-N-4-nitrobenzylglycine hydroxamates using LFER model, Drug Design and Discovery, 17, 315 Scozzafava, 2000, Protease inhibitors: Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties, Journal of Medicinal Chemistry, 43, 1858, 10.1021/jm990594k Skiles, 2001, The design, structure, and therapeutic application of matrix metalloproteinase inhibitors, Current Medicinal Chemistry, 8, 425, 10.2174/0929867013373417 Stephen, 2001, N-aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: Further probing of the S1, S1, and S2 pockets, Journal of Medicinal Chemistry, 44, 3066, 10.1021/jm010097f Stetler-Stevenson, 1999, Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention, Journal of Clinical Investigation, 103, 1237, 10.1172/JCI6870 Subramaniam, 2009, Natural products as inhibitors of matrix metalloproteinases, 54 Summers, 1998, Matrix metalloproteinase inhibitors and cancer, Annual Reports in Medicinal Chemistry, 33, 131, 10.1016/S0065-7743(08)61078-7 van Montfort, 2009, Structure-based design of molecular cancer therapeutics, Trends in Biotechnology, 27, 315, 10.1016/j.tibtech.2009.02.003 Vihinen, 2002, Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets, International Journal of Cancer, 99, 157, 10.1002/ijc.10329 Weinstat-Saslow, 1994, Angiogenesis and colonization in the tumor metastatic process: Basic and applied advances, FASEB Journal, 8, 401, 10.1096/fasebj.8.6.7513289 Wilson, 2012, Computational strategies in cancer drug discovery, Advances in Cancer Management, 237 Wold, 1991, Validation of QSAR's, Quantitative Structure-Activity Relationships, 10, 191, 10.1002/qsar.19910100302 Yu, 2000, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis, Genes & Development, 14, 163, 10.1101/gad.14.2.163 Zask, 1996, Inhibition of matrix metalloproteinases: Structure based design, Current Pharmaceutical Design, 2, 624, 10.2174/1381612802666221004190555 Zheng, 2008, Three-dimensional quantitative structure–activity relationship (CoMFA and CoMSIA) studies on galardin derivatives as gelatinase A (matrix metalloproteinase 2) inhibitors, Journal of Enzyme Inhibition and Medicinal Chemistry, 23, 445, 10.1080/14756360701632221